Sun Pharma Advanced Research Company Ltd

The Sensex gained 1.13% on 12 Jun 2026, but Sun Pharma Advanced Research Company Ltd (SPARC) outpaced the broader market with a robust 7.4% rally, touching an intraday high of Rs 221.75. This 6.34 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific momentum shift rather than a mere market tailwind.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was adjusted on that date, the analysis below reflects the stock's current fundamentals, returns, and financial metrics as of 08 June 2026, providing investors with an up-to-date perspective on the company’s standing.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date insight into its performance and outlook.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its technical momentum, moving from a strongly bullish stance to a more tempered mildly bullish trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a nuanced outlook for investors navigating the pharmaceuticals and biotechnology sector.

Sun Pharma Advanced Research Company Ltd (SPARC) has recently experienced a downgrade in its quality grade from 'Good' to 'Average' as of 22 May 2026, reflecting shifts in its business fundamentals. Despite a strong five-year sales growth of nearly 399%, the company’s return metrics and capital efficiency have shown signs of deterioration, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd experienced a significant intraday decline on 1 June 2026, touching a low of Rs 196.45, down 7.29% from the previous close. The stock underperformed its sector and the broader market amid a sharp reversal in market sentiment, reflecting immediate selling pressure and cautious trading activity.

Sun Pharma Advanced Research Company Ltd (SPARC) has delivered an exceptional quarterly performance for the period ending March 2026, prompting an upgrade in its Mojo Grade from Buy to Strong Buy. The pharmaceutical innovator posted record-breaking revenue and profit metrics, signalling a significant turnaround in its financial trajectory and reinforcing its position within the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of the stock’s price attractiveness amid a volatile market backdrop and evolving sector dynamics.

Sun Pharma Advanced Research Company Ltd (SPARC) experienced a notable decline today, touching an intraday low of Rs 217.5, reflecting a 7.35% drop amid broad price pressures. The stock underperformed its sector and the broader market, reversing gains after three consecutive days of upward movement.

With a decisive surge to Rs 244.5 on 26 Jun 2026, Sun Pharma Advanced Research Company Ltd has reached a fresh 52-week high, marking a remarkable 47.67% gain over the past year against a Sensex decline of 6.84%. This milestone reflects a powerful alignment of technical indicators and sustained price momentum that has propelled the stock well above its key moving averages.

With a decisive surge to Rs 233.8 on 25 Jun 2026, Sun Pharma Advanced Research Company Ltd has reached a fresh 52-week high, reflecting a powerful alignment of technical indicators and sustained price momentum that has propelled the stock well above its previous resistance levels.

The Sensex rose 1.18% on 25 May 2026, yet Sun Pharma Advanced Research Company Ltd outpaced the broader market with an 11.24% gain, touching a new 52-week high of Rs 233.8. This 9.12 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.

Sun Pharma Advanced Research Company Ltd (SPARC) has seen its investment rating revised from Strong Buy to Buy as of 22 May 2026, reflecting significant changes across financial performance, quality metrics, valuation, and technical indicators. Despite the downgrade, the company continues to demonstrate robust growth and market-beating returns, supported by a remarkable quarterly performance and improving fundamentals.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating adjustment occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 23 May 2026, providing investors with the latest insights into its performance and outlook.